Company news
Citius Oncology, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe
November 4, 2026
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
October 26, 2026
Citius Pharmaceuticals to Participate in October 2026 Investor Conferences
October 12, 2026
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
August 14, 2026
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
August 12, 2026
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
August 5, 2026
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
July 21, 2026
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
June 1, 2026
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
May 26, 2026
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
May 15, 2026
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization
May 4, 2026
Citius Oncology Ships First International Order of LYMPHIR™ to Europe
April 29, 2026
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
March 30, 2026
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts
March 23, 2026
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
March 9, 2026
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
March 4, 2026
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
February 13, 2026
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
February 12, 2026
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
February 11, 2026
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
December 23, 2025
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
December 22, 2025
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
December 10, 2025
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
December 9, 2025
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
December 4, 2025
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
December 1, 2025
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
November 25, 2025
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
November 21, 2025
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch
October 20, 2025
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
October 17, 2025
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™
October 16, 2025
Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe
October 7, 2025
Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
September 10, 2025
Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
September 9, 2025
Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch
August 22, 2025
Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
August 12, 2025
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
August 11, 2025
Citius Oncology Announces Closing of $9.0 Million Public Offering
July 17, 2025
Citius Oncology Announces Pricing of $9.0 Million Public Offering
July 16, 2025
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora
July 15, 2025
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025
June 17, 2025
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health
June 9, 2025
Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update
May 14, 2025
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
May 4, 2025
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
February 13, 2025
Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
February 13, 2025
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
February 5, 2025
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
January 6, 2025
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
January 5, 2025
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
December 26, 2024
Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
December 26, 2024
Decks
- Investor Presentation (December 2025)
Investor deck · 19 slides · Dec 1, 2025
- Investor Presentation (October 2025)
Investor deck · 19 slides · Oct 23, 2025
- SPAC Merger (October 2023)
SPAC merger · 33 slides · Oct 24, 2023